Tegretol Does NOT Require Fasting for Therapeutic Drug Monitoring
Carbamazepine (Tegretol) therapeutic drug monitoring does not require fasting, and blood samples should be collected as trough levels (before the morning dose) regardless of fasting status.
Timing of Sample Collection
The critical factor for carbamazepine monitoring is timing relative to dosing, not fasting status:
- Trough levels (collected immediately before the next dose, typically after an overnight period) are the standard for therapeutic drug monitoring 1
- The therapeutic range for carbamazepine is 4-12 µg/mL 2
- Trough levels should be aimed at 6-8 mg/L to ensure therapeutic efficacy while avoiding toxicity 3
Why Fasting Is Not Required
Research demonstrates that food has minimal clinical impact on carbamazepine bioavailability:
- A study of slow-release carbamazepine formulations showed only small increases in AUC and Cmax when given with food, with bioequivalence maintained between fasting and fed states 4
- The conclusion was that "administration of carbamazepine slow-release formulation to patients in the fasting or nonfasting state seems not to be a major consideration when deciding on the regimen" 4
Clinical Monitoring Recommendations
The key principle is consistent timing:
- Collect samples before the morning dose (trough level) 1
- This typically occurs after an overnight period, but the overnight fast is incidental to timing, not a requirement
- Peak levels (2-4 hours post-dose) should not exceed 10-12 mg/L to avoid adverse effects 5, 3
- Measuring only trough values "sufficiently estimates clinical response" except in patients showing side effects 1
Common Pitfall to Avoid
Do not confuse the overnight period before morning dosing with a fasting requirement. The overnight period simply ensures you're capturing a trough level at a consistent time point. Patients can take their medication with meals as directed in the FDA label 6, and blood draws for monitoring should focus on pre-dose timing rather than fasting status.